Naloxone Hydrochloride Mercury Pharmaceuticals (Ireland) (Naloxone Hydrochloride)

Naloxone Hydrochloride works by competitively binding to μ‑opioid receptors in the central nervous system. By displacing opioid agonists from these receptors, it blocks their depressant actions, allowing the respiratory centers and level of consciousness to recover quickly without producing opioid effects itself.

The dose of Naloxone Hydrochloride is determined by the prescribing clinician based on the severity of the opioid exposure, the patient’s age, weight, and clinical response. Healthcare professionals follow established protocols and may repeat dosing if the opioid effect persists.

Safety data for Naloxone Hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Naloxone Hydrochloride, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Naloxone is the most widely used opioid antagonist because of its rapid onset and short duration of action, making it ideal for emergency reversal. Compared with longer‑acting agents such as nalmefene, naloxone may require repeat dosing but provides quicker symptom relief, which is critical in acute overdose situations.

Naloxone Hydrochloride should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and avoid exposing it to temperatures above the recommended range to maintain potency.

Naloxone is supplied as an injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route is chosen by the healthcare professional based on the clinical situation, with intramuscular injection being common in pre‑hospital emergency care.

Serious risks, although rare, include acute hypertension, cardiac arrhythmias, seizures, pulmonary edema, and severe allergic reactions such as anaphylaxis. Immediate medical evaluation is required if any of these events occur after administration.

Naloxone is contraindicated in individuals with known hypersensitivity to naloxone or any of its excipients. Caution is also advised in patients with severe cardiovascular disease, as rapid reversal of opioid effects can precipitate hypertension or arrhythmias.